Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Influenza, Human × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 93 Carcinoma, Non-Small-Cell Lung 30 Carcinoma, Renal Cell 21 Prostatic Neoplasms 14 Neoplasm Metastasis 14 Brain Neoplasms 12 Neoplasms 11 Lung Neoplasms 11 Breast Neoplasms 11 Uveal Melanoma 9 Sarcoma 9 Pancreatic Neoplasms 9 Small Cell Lung Carcinoma 7 Urinary Bladder Neoplasms 6 Kidney Neoplasms 6 Carcinoma, Transitional Cell 6 Carcinoma, Hepatocellular 6 Squamous Cell Carcinoma of Head and Neck 5 Skin Neoplasms 5 Ovarian Neoplasms 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Histiocytoma, Malignant Fibrous 4 Colonic Neoplasms 4 Urogenital Neoplasms 3 Recurrence 3 Rectal Neoplasms 3 Osteosarcoma 3

Interventions

Influenza Vaccines 5 trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2 Vaccines 2 thymoglobulin 1 fludarabine 1 baloxavir 1 Rituximab 1 Oseltamivir 1 Nivolumab 1 Melphalan 1 Levetiracetam 1 Ipilimumab 1 Fluzone High-Dose 1 Cyclophosphamide 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05116917 2024-05-28

INFLUENCE

Herlev Hospital

Phase 2 Terminated

Gastrointestinal

Influenza, Human, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡